PE20090247A1 - AMINO-HETEROCICLIC COMPOUNDS - Google Patents

AMINO-HETEROCICLIC COMPOUNDS

Info

Publication number
PE20090247A1
PE20090247A1 PE2008000812A PE2008000812A PE20090247A1 PE 20090247 A1 PE20090247 A1 PE 20090247A1 PE 2008000812 A PE2008000812 A PE 2008000812A PE 2008000812 A PE2008000812 A PE 2008000812A PE 20090247 A1 PE20090247 A1 PE 20090247A1
Authority
PE
Peru
Prior art keywords
alkyl
compounds
pyrimidin
pyridinyl
cycloalkyl
Prior art date
Application number
PE2008000812A
Other languages
Spanish (es)
Inventor
Patrick Robert Verhoest
Caroline Proulx-Lafrance
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20090247A1 publication Critical patent/PE20090247A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA I, DONDE R ES ALQUILO(C1-C6), ALQUINILO(C2-C6), CICLOALQUILO(C3-C8), ENTRE OTROS; R1 ES H, ALQUENILO(C2-C4), HALOALQUILO(C1-C4), ENTRE OTROS; R2 ES ALQUILO(C1-C6), PIRIDINILO, PIRIDAZINILO, ER5, ENTRE OTROS; R3 ES H, ALQUILO(C1-C4), ALQUENILO(C2-C4), ALQUINILO(C2-C4), ENTRE OTROS; E ES -CH2-, -CH2CH2-, -CH2CH2CH2- Y -C(O)-; R5 ES CICLOALQUILO(C3-C8), MORFOLINILO, BENCIMIDAZOLILO, IMIDAZO[1,2-a]PIRIDINILO, ENTRE OTROS. SON SELECCIONADOS 6-[(3S,4S)-1-BENCIL-4-METILPIRROLIDIN-3-IL]-1-CICLOPENTIL-1,5-DIHIDRO-4H-PIRAZOLO[3,4-d]PIRIMIDIN-4-ONA, 4-({(3S,4S)-3-ETIL-4-[4-OXO-1-(TETRAHIDRO-2H-PIRAN-4-IL)-4,5-DIHIDRO-1H-PIRAZOLO[3,4-d]PIRIMIDIN-6-IL]PIRROLIDIN-1-IL}METIL)BENZONITRILO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCESO DE PREPARACION Y COMPOSICION FARMACEUTICA, OPCIONALMENTE CON UN SEGUNDO COMPUESTO ACTIVO ADICIONAL TAL COMO, DONEPEZILO, GALANTAMINA, MEMANTINA, RIVASTIGMINA Y TACRINA. DICHOS COMPUESTOS SON INHIBIDORES DE PDE9 UTIL EN EL TRATAMIENTO DE TRASTORNOS NEURODEGENERATIVOS Y COGNITIVOSREFERS TO COMPOUNDS OF FORMULA I, WHERE R IS ALKYL (C1-C6), ALKINYL (C2-C6), CYCLOALKYL (C3-C8), AMONG OTHERS; R1 IS H, ALKENYL (C2-C4), HALOALKYL (C1-C4), AMONG OTHERS; R2 IS (C1-C6) ALKYL, PYRIDINYL, PYRIDAZINYL, ER5, AMONG OTHERS; R3 IS H, ALKYL (C1-C4), ALKENYL (C2-C4), ALKYNYL (C2-C4), AMONG OTHERS; E IS -CH2-, -CH2CH2-, -CH2CH2CH2- AND -C (O) -; R5 IS CYCLOALKYL (C3-C8), MORPHOLINYL, BENZYMIDAZOLYL, IMIDAZO [1,2-a] PYRIDINYL, AMONG OTHERS. ARE SELECTED 6 - [(3S, 4S) -1-BENZYL-4-METHYLPYRROLIDIN-3-IL] -1-CYCLOPENTIL-1,5-DIHIDRO-4H-PIRAZOLO [3,4-d] PYRIMIDIN-4-ONA, 4 - ({(3S, 4S) -3-ETHYL-4- [4-OXO-1- (TETRAHYDRO-2H-PYRAN-4-IL) -4,5-DIHYDRO-1H-PYRAZOLO [3,4-d ] PYRIMIDIN-6-IL] PYRROLIDIN-1-IL} METHYL) BENZONITRILE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL PREPARATION AND COMPOSITION PROCESS, OPTIONALLY WITH A SECOND ADDITIONAL ACTIVE COMPOUND SUCH AS DONEPEZILO, GALANTAMINE, MEMANTINE, RIVASTIGMINE AND TACRINE. SUCH COMPOUNDS ARE INHIBITORS OF PDE9 USEFUL IN THE TREATMENT OF NEURODEGENERATIVE AND COGNITIVE DISORDERS

PE2008000812A 2007-05-11 2008-05-08 AMINO-HETEROCICLIC COMPOUNDS PE20090247A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91733307P 2007-05-11 2007-05-11

Publications (1)

Publication Number Publication Date
PE20090247A1 true PE20090247A1 (en) 2009-03-13

Family

ID=39672073

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000812A PE20090247A1 (en) 2007-05-11 2008-05-08 AMINO-HETEROCICLIC COMPOUNDS

Country Status (44)

Country Link
US (1) US7964607B2 (en)
EP (1) EP2152712B1 (en)
JP (1) JP4579346B2 (en)
KR (1) KR101222330B1 (en)
CN (1) CN101687876B (en)
AP (1) AP2524A (en)
AR (1) AR066502A1 (en)
AT (1) ATE540954T1 (en)
AU (1) AU2008249750B2 (en)
BR (1) BRPI0811280B8 (en)
CA (1) CA2687035C (en)
CL (1) CL2008001374A1 (en)
CO (1) CO6241157A2 (en)
CR (1) CR11095A (en)
CU (1) CU23834B1 (en)
CY (1) CY1112332T1 (en)
DK (1) DK2152712T3 (en)
DO (1) DOP2009000258A (en)
EA (1) EA016510B1 (en)
EC (1) ECSP099728A (en)
ES (1) ES2377849T3 (en)
GE (1) GEP20125405B (en)
GT (1) GT200900294A (en)
HK (1) HK1142595A1 (en)
HR (1) HRP20120105T1 (en)
IL (1) IL201977A (en)
MA (1) MA31373B1 (en)
ME (1) ME00954B (en)
MX (1) MX2009011830A (en)
MY (1) MY147330A (en)
NI (1) NI200900204A (en)
NZ (1) NZ580904A (en)
PA (1) PA8779901A1 (en)
PE (1) PE20090247A1 (en)
PL (1) PL2152712T3 (en)
PT (1) PT2152712E (en)
RS (1) RS52166B (en)
SI (1) SI2152712T1 (en)
SV (1) SV2009003411A (en)
TN (1) TN2009000471A1 (en)
TW (1) TWI362262B (en)
UA (1) UA94660C2 (en)
WO (1) WO2008139293A1 (en)
ZA (1) ZA200907776B (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (en) 2001-12-27 2003-07-10 Bayer Ag 2-heteroaryl carboxamides
DE10238722A1 (en) 2002-08-23 2004-03-11 Bayer Ag Improving attention, concentration, cognition, learning and/or memory performance, using selective phosphodiesterase 9A inhibitors, preferably 4H-pyrazolo-(3,4-d)-pyrimidin-4-one derivatives
PE20091211A1 (en) 2007-11-30 2009-09-14 Boehringer Ingelheim Int PYRAZOLOPYRIMIDINE DERIVATIVES AS PDE9A MODULATORS
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
PE20110383A1 (en) 2008-09-08 2011-07-15 Boehringer Ingelheim Int PYRAZOLOPYRIMIDINONES AS INHIBITORS OF PHOSPHODIESTERASE 9A (PDE9A)
EP2540297B1 (en) 2008-11-19 2015-04-08 Forum Pharmaceuticals Inc. Treatment of Cognitive Disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TWI404721B (en) 2009-01-26 2013-08-11 Pfizer Amino-heterocyclic compounds
CA2757231A1 (en) 2009-03-31 2010-10-07 Boehringer Ingelheim International Gmbh 1-heterocyclyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
RU2011150248A (en) * 2009-05-11 2013-06-20 Энвиво Фармасьютикалз, Инк. TREATMENT OF COGNITIVE DISORDERS WITH SPECIFIC ALPHA-7 NICOTIN ACID RECEPTORS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS
JP2012526810A (en) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド Organic compounds
EP2485771A4 (en) * 2009-10-08 2014-11-12 Intra Cellular Therapies Inc Phosphodiesterase 1-targeting tracers and methods
CN105837566B (en) 2010-05-17 2018-02-06 富瑞姆制药公司 (R) crystal formation of the carboxamide hydrochloride monohydrate of 7 chlorine N (base of quinuclidine 3) benzo [b] thiophene 2
PL2603511T3 (en) 2010-08-12 2017-08-31 Boehringer Ingelheim Int 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
DK2615089T3 (en) 2010-09-07 2016-06-06 Astellas Pharma Inc Pyrazoloquinolinforbindelser
CN103313988B (en) 2010-09-20 2016-06-08 论坛医药有限公司 Imidazo-triazine ketonic compound
US20130040971A1 (en) * 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
IN2014CN02463A (en) 2011-10-07 2015-06-19 Eisai R&D Man Co Ltd
CN106905324B (en) 2011-10-10 2018-09-25 H.隆德贝克有限公司 PDE9 inhibitor with Imidazopyrazines ketone skeleton
SG11201403909RA (en) 2012-01-26 2014-10-30 Lundbeck & Co As H Pde9 inhibitors with imidazo triazinone backbone
WO2013142269A1 (en) * 2012-03-19 2013-09-26 Envivo Pharmaceuticals, Inc. Imidazotriazinone compounds
EP2846796A4 (en) 2012-05-08 2015-10-21 Forum Pharmaceuticals Inc Methods of maintaining, treating or improving cognitive function
JP6189948B2 (en) 2012-06-29 2017-08-30 ファイザー・インク Novel 4- (substituted amino) -7H-pyrrolo [2,3-d] pyrimidines as LRRK2 inhibitors
WO2014024125A1 (en) 2012-08-08 2014-02-13 Celon Pharma S.A. Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
EP2956141A4 (en) 2013-02-17 2016-10-26 Intra Cellular Therapies Inc Novel uses
EP2982675B1 (en) 2013-04-05 2017-08-16 Eisai R&D Management Co., Ltd. Salt of pyrazoloquinoline derivative, and crystal thereof
AU2014250391B2 (en) * 2013-04-05 2017-11-02 Eisai R&D Management Co., Ltd. Pyridinylpyrazoloquinoline compound
CN103626774B (en) * 2013-11-20 2015-11-04 苏州明锐医药科技有限公司 Yi Lu is for the preparation method of Buddhist nun
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
ES2745819T3 (en) 2014-08-07 2020-03-03 Intra Cellular Therapies Inc Imidazo [1,2-a] -pyrazolo [4,3-e] -pyrimidin-4-one derivatives with PDE1 inhibitory activity
CN107106563B (en) * 2014-09-17 2021-05-25 细胞内治疗公司 Compounds and methods
TW201629064A (en) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 Triazolopyrainones as PDE1 inhibitors
BR112017012005B1 (en) 2014-12-06 2023-04-04 Intra-Cellular Therapies, Inc ORGANIC PDE2-INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS AND USE THEREOF IN THE TREATMENT OF A PDE2-MEDIATED DISORDER
EP3226870B1 (en) 2014-12-06 2019-09-25 Intra-Cellular Therapies, Inc. Organic compounds
EP3237401B1 (en) 2014-12-22 2019-03-06 Pfizer Inc Antagonists of prostaglandin ep3 receptor
JO3627B1 (en) 2015-04-30 2020-08-27 H Lundbeck As Imidazopyrazinones as PDE1 inhibitors
AU2016289856B2 (en) 2015-07-07 2020-11-26 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
WO2017046675A1 (en) 2015-09-14 2017-03-23 Pfizer Inc. Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
WO2017048720A1 (en) 2015-09-15 2017-03-23 Praxis Biosciences, Llc Prodrugs of fencamfamine
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
EP3362455A1 (en) 2015-10-16 2018-08-22 AbbVie Inc. PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
CN105669680B (en) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 (1H) ketone derivatives class PDE9A inhibitor of pyrrolo- [2,1 f] [1,2,4] triazine 4
EP3436083A4 (en) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. Novel compositions and methods
TWI729109B (en) * 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 1,5-DIHYDRO-4H-PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND 1,5-DIHYDRO-4H-PYRAZOLO[4,3-c]PYRIDIN-4-ONES AS PDE1 INHIBITORS
EP3481398A1 (en) 2016-07-06 2019-05-15 Imara, Inc. Pde9 inhibitors for treatment of peripheral diseases
WO2018073251A1 (en) 2016-10-18 2018-04-26 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
JP2020500841A (en) 2016-10-28 2020-01-16 ハー・ルンドベック・アクチエゼルスカベット Combination therapy including imidazopyrazinone administration
WO2018078038A1 (en) 2016-10-28 2018-05-03 H. Lundbeck A/S Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
CN110337437B (en) 2016-12-28 2023-02-03 达特神经科学有限公司 Substituted pyrazolopyrimidinones as PDE2 inhibitors
HRP20240146T1 (en) * 2017-05-26 2024-04-12 Cardurion Pharmaceuticals, Inc. Methods of making and using pde9 inhibitors
RU2019135261A (en) 2017-06-01 2021-07-09 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. PHARMACEUTICAL COMPOSITION CONTAINING PDE9 INHIBITOR
AU2018278422B2 (en) 2017-06-01 2022-03-17 Eisai R&D Management Co., Ltd. Lewy body disease therapeutic agent containing pyrazoloquinoline derivative
JP7079777B2 (en) 2017-06-01 2022-06-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 Dementia treatment agent by combined use of pyrazoloquinoline derivative and donepezil
CN110603039B (en) * 2017-06-01 2023-02-28 卫材R&D管理有限公司 Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
EP3634964B1 (en) 2017-06-08 2022-02-23 Merck Sharp & Dohme Corp. Pyrazolopyrimidine pde9 inhibitors
CA3120971A1 (en) 2017-11-27 2019-05-31 Dart Neuroscience, Llc Substituted furanopyrimidine compounds as pde1 inhibitors
JP7401442B2 (en) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド new use
CN110357888A (en) * 2018-04-09 2019-10-22 南京药捷安康生物科技有限公司 Heterocycle phosphodiesterase inhibitors and application thereof
SI3801526T1 (en) 2018-05-25 2024-05-31 Cardurion Pharmaceuticals, Inc. Monohydrate and crystalline forms of 6-((3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-tetrahydropyran-4-yl- 7h-imid azo (1,5- a) pyrazin-8-one
US20210379072A1 (en) * 2018-10-21 2021-12-09 Intra-Cellular Therapies, Inc. Novel uses
KR20200068994A (en) * 2018-12-06 2020-06-16 한국화학연구원 Compound for inhibiting PDE9A and medical uses thereof
CN111471059B (en) 2019-01-23 2022-12-02 药捷安康(南京)科技股份有限公司 PDE9 inhibitors and uses thereof
US12012412B2 (en) 2021-12-16 2024-06-18 Pfizer Inc. Solid forms of pyrazolo[3,4-d]pyrimidine compounds
WO2023156386A2 (en) * 2022-02-16 2023-08-24 Duke Street Bio Limited Pharmaceutical compound

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020156277A1 (en) 2001-04-20 2002-10-24 Fick David B. Synthesis and methods of use of purine analogues and derivatives
WO2002094790A1 (en) 2001-05-23 2002-11-28 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
HN2002000317A (en) * 2001-11-02 2003-05-21 Pfizer PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS
MXPA04004170A (en) * 2001-11-02 2004-09-06 Pfizer Prod Inc Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors.
US7110628B2 (en) * 2002-07-12 2006-09-19 Massachusetts Institute Of Technology Reconfigurable microphotonics devices via deformable membrane platforms
DE10238722A1 (en) * 2002-08-23 2004-03-11 Bayer Ag Improving attention, concentration, cognition, learning and/or memory performance, using selective phosphodiesterase 9A inhibitors, preferably 4H-pyrazolo-(3,4-d)-pyrimidin-4-one derivatives
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US7051174B2 (en) * 2002-09-24 2006-05-23 International Business Machines Corporation Method, system, and program for restoring data in cache
EP1553947A4 (en) 2002-10-21 2006-11-29 Bristol Myers Squibb Co Quinazolinones and derivatives thereof as factor xa inhibitors
US7111287B2 (en) * 2003-01-10 2006-09-19 International Business Machines Corporation Global processor resource assignment in an assembler
EP1460077B1 (en) 2003-03-18 2007-08-01 The Jordanian Pharmaceutical Manufacturing Co. Ltd. Novel pyrazolopyrimidones and their use as PDE inhibitors
EP1608317B1 (en) 2003-03-25 2012-09-26 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
DE10320785A1 (en) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-arylmethyl substituted pyrazolopyrimidines

Also Published As

Publication number Publication date
ECSP099728A (en) 2009-12-28
CY1112332T1 (en) 2015-12-09
TW200902015A (en) 2009-01-16
UA94660C2 (en) 2011-05-25
HK1142595A1 (en) 2010-12-10
PL2152712T3 (en) 2012-05-31
US7964607B2 (en) 2011-06-21
CA2687035C (en) 2011-09-20
NI200900204A (en) 2010-03-11
EP2152712B1 (en) 2012-01-11
TN2009000471A1 (en) 2011-03-31
EA200901373A1 (en) 2010-06-30
DOP2009000258A (en) 2010-05-15
IL201977A0 (en) 2010-06-16
RS52166B (en) 2012-08-31
NZ580904A (en) 2012-02-24
JP4579346B2 (en) 2010-11-10
SI2152712T1 (en) 2012-03-30
BRPI0811280B1 (en) 2021-05-11
CR11095A (en) 2009-12-04
ATE540954T1 (en) 2012-01-15
PA8779901A1 (en) 2008-12-18
AU2008249750B2 (en) 2011-07-14
CU23834B1 (en) 2012-10-15
BRPI0811280A2 (en) 2015-01-20
ME00954B (en) 2012-06-20
GEP20125405B (en) 2012-02-27
EP2152712A1 (en) 2010-02-17
AP2524A (en) 2012-12-04
WO2008139293A1 (en) 2008-11-20
AR066502A1 (en) 2009-08-26
HRP20120105T1 (en) 2012-02-29
MY147330A (en) 2012-11-30
BRPI0811280B8 (en) 2021-05-25
DK2152712T3 (en) 2012-03-26
US20090030003A1 (en) 2009-01-29
AP2009005048A0 (en) 2009-12-31
CO6241157A2 (en) 2011-01-20
EA016510B1 (en) 2012-05-30
ES2377849T3 (en) 2012-04-02
PT2152712E (en) 2012-02-29
IL201977A (en) 2014-07-31
MX2009011830A (en) 2009-11-13
SV2009003411A (en) 2010-05-21
KR20100007985A (en) 2010-01-22
TWI362262B (en) 2012-04-21
CU20090184A7 (en) 2011-07-11
CN101687876A (en) 2010-03-31
CN101687876B (en) 2012-12-12
GT200900294A (en) 2011-08-29
JP2010526863A (en) 2010-08-05
KR101222330B1 (en) 2013-01-15
ZA200907776B (en) 2011-01-26
MA31373B1 (en) 2010-05-03
AU2008249750A1 (en) 2008-11-20
CL2008001374A1 (en) 2008-11-14
CA2687035A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
PE20090247A1 (en) AMINO-HETEROCICLIC COMPOUNDS
AR080785A1 (en) DERIVATIVES OF IMIDAZO [1,2-A] PYRIMIDINE, PROCESS TO PREPARE THEM AND INTERMEDIARIES OF SUCH SYNTHESIS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THEM IN THE TREATMENT OF PATHOLOGIES OF THE CENTRAL NERVOUS SYSTEM, SUCH AS PARK AND OTHERS.
PE20110922A1 (en) DERIVATIVES OF PIRAZOLO [4,3-e] PYRIMIDIN AS INHIBITORS OF PHOSPHODIESTERASE 1 (PDE1)
PE20091561A1 (en) RAF INHIBITING COMPOUNDS AND METHODS FOR THEIR USE
PE20130234A1 (en) DERIVATIVES OF HETEROARYL IMIDAZOLONE AS JAK INHIBITORS
PE20151249A1 (en) PYRAZOLOPYRIMIDINE DERIVATIVES AS INHIBITORS OF JAK KINASES
PE20110387A1 (en) AMINOTRIAZOLO-PYRIDINES AS KINASE INHIBITORS
PE20120209A1 (en) DERIVATIVES OF IMIDAZO- [1,2-a] -PIRAZOLO [4,3-e] PYRIMIDINE OR PYRIMIDO- [1,2-a] -PIRAZOLO [4,3-e] PYRIMIDINE AS INHIBITORS OF PHOSPHODIESTERASE 1 (PDE1)
PE20181198A1 (en) DERIVATIVES OF CONDENSED BICYCLE HETEROCYCLES AS PEST CONTROL AGENTS
HRP20151250T1 (en) Isoxazolo-pyridine derivatives
PE20030155A1 (en) AZAINDOLS AS KINASE INHIBITORS
PE20081888A1 (en) PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS INHIBITORS OF mTOR KINASE AND PI3 KINASE
PE20110828A1 (en) PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS
PE20080552A1 (en) DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYLENE ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS
PE20161372A1 (en) ROR-GAMMA DIHYDROPYRROLOPYRIDINE INHIBITORS
AR088029A1 (en) SUBSTITUTED PYRIMIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME FOR THE TREATMENT OF PAIN, CEREBROVASCULAR ACCIDENTS, EPILEPSY AND OTHER DISEASES OF THE CENTRAL NERVOUS SYSTEM
SV2006002110A (en) THERAPEUTIC COMPOUNDS REF. PC32293A
PE20081612A1 (en) PTERINAL ANALOGS
ECSP077424A (en) DERIVATIVES OF QUINUCLIDINE AND ITS USE AS ANTAGONIST OF THE M3 MUSCARINIC RECEIVER
AR076749A1 (en) PIRROLO [2, 3 - B] PYRIDINS AS INHIBITORS OF THE PROTEIN QUINASAS RAF
MX2009010728A (en) Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors.
AR070526A1 (en) UREA DERIVATIVES OF BENZOMORPHANS AND RELATED STRUCTURES, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMPOUND AND A PREPARATION PROCEDURE OF THE SAME
PE20110383A1 (en) PYRAZOLOPYRIMIDINONES AS INHIBITORS OF PHOSPHODIESTERASE 9A (PDE9A)
PE20120534A1 (en) PYRIMIDINES FUSED AS INHIBITORS OF Akt
PE20070021A1 (en) TRIAZOLOPYRIDINE COMPOUNDS AS CANABINOID 1 RECEPTOR ANTAGONISTS

Legal Events

Date Code Title Description
FG Grant, registration